Other mutations in KMT2D, KRAS (in-frame deletion), and FRAT2 (FRAT regulator of WNT signaling pathway 2) are potentially associated with the oncogenesis of parathyroid carcinoma; however, the evidence remains limited. The gene discussed is KMT2D; the disease is parathyroid gland carcinoma.